Scilex Holding (SCLXW) Cost of Revenue (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly Cost of Revenue of $4.4 million in Q1 2026, up 70.12% quarter-over-quarter from $2.6 million in Q4 2025, and up 221.32% on a YoY basis from $1.4 million in Q1 2025.
Scilex Holding (SCLXW) Cost of Revenue (2022 - 2026) Analysis & Trends
Scilex Holding's Cost of Revenue history runs 5 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- In Q1 2026, Cost of Revenue rose 221.32% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $13.7 million (down 4.01% YoY), while the FY2025 annual figure was $10.6 million, down 36.49% from the prior year.
- Cost of Revenue was $4.4 million for Q1 2026 at Scilex Holding, up from $2.6 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $4.7 million in Q4 2024 to a low of $1.1 million in Q1 2022.
- Historically, Cost of Revenue has averaged $3.4 million across 5 years, with a median of $3.6 million in 2022.
- The sharpest annual moves came in 2025 and 2026: Cost of Revenue plunged 63.96% in 2025, then jumped 221.32% in 2026.
- A 5-year view of Cost of Revenue shows it stood at $4.5 million in 2022, then advanced by 0.18% to $4.5 million in 2023, then climbed by 3.76% to $4.7 million in 2024, then sank by 44.28% to $2.6 million in 2025, then soared by 70.12% to $4.4 million in 2026.
- The last three Cost of Revenue figures came in at $4.4 million (Q1 2026), $2.6 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.53 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 3.58 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 8.11 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 4.22 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 4.20 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.74 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.45 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 3.55 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 3.42 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.45 Mn |
| Mar 31, 2026 | 4.45 Mn |
| Dec 31, 2025 | 2.61 Mn |
| Dec 31, 2025 | 2.61 Mn |
| Sep 30, 2025 | 3.33 Mn |
| Sep 30, 2025 | 3.33 Mn |
| Jun 30, 2025 | 3.27 Mn |
| Jun 30, 2025 | 3.27 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Sep 30, 2024 | 3.77 Mn |
| Sep 30, 2024 | 3.77 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Mar 31, 2024 | 3.84 Mn |
| Mar 31, 2024 | 3.84 Mn |
| Dec 31, 2023 | 4.52 Mn |
| Dec 31, 2023 | 4.52 Mn |